Ceapro Inc. to Present at the H.C. Wainwright Global Investment Conference
EDMONTON, Alberta, May 23, 2022 (GLOBE NEWSWIRE) — Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro”…
News
Praxis Precision Medicines Adds Global Business Expertise to Board of Directors with Appointment of Jill DeSimone
BOSTON, May 23, 2022 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage…
Revelation Biosciences Inc. Announces Safety Monitoring Committee Recommendation for Continuing Evaluation of REVTx-99b for the Treatment of Allergic Rhinitis
Top-line data anticipated in the Q3 2022 SAN DIEGO, May 23, 2022 (GLOBE NEWSWIRE) —…
CytoDyn Announces Resolution of Legal Dispute with Former Chief Medical Officer
VANCOUVER, Washington, May 23, 2022 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the…
NYMOX Receives RTF letter from FDA
IRVINE, Calif., May 23, 2022 (GLOBE NEWSWIRE) — Nymox Pharmaceutical Corporation (NASDAQ: NYMX) reports today…
Journey Medical Corporation to Present at the B. Riley Securities 22nd Annual Institutional Investor Conference
SCOTTSDALE, Ariz., May 23, 2022 (GLOBE NEWSWIRE) — Journey Medical Corporation (“Journey Medical”) (NADSAQ: DERM),…
Catalyst Biosciences Sells Complement Portfolio for $60 Million
SOUTH SAN FRANCISCO, Calif., May 23, 2022 (GLOBE NEWSWIRE) — Catalyst Biosciences, Inc. (NASDAQ: CBIO)…
Albireo Presented Data in Cholestatic Liver Diseases at Digestive Disease Week (DDW) 2022
– Six abstracts presented highlighting data on BylvayTM(odevixibat) and effects on pruritus, serum bile acids,…
Day One Announces First Patients Dosed in Phase 1b/2 Combination Study with Tovorafenib (DAY101) and Pimasertib in RAF-altered Solid Tumors
Phase 1b/2 combination study, FIRELIGHT-1, to leverage insights from pediatric development to evaluate potential synergistic…
Innoviva to Acquire Entasis Therapeutics
Innoviva to acquire all outstanding shares of Entasis it does not already own for $2.20…
Quoin Pharmaceuticals Enters Exclusive Research Agreement for Scleroderma Treatment with Australian University
Quoin obtains option to exclusive global rights to product; no upfront or milestone fees ASHBURN,…
Umoja Biopharma and Lupagen Announce New Collaboration to Improve Patient Experience and Access to Next-Generation In Vivo Therapeutics for Cancer
The partnership will evaluate Lupagen’s extracorporeal in vivo delivery technology as a potential additional route…
IO Biotech to Participate in the Jefferies Healthcare Conference
NEW YORK, May 23, 2022 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical…
CymaBay Therapeutics Presents New Findings that Seladelpar Treatment of PBC Patients for Two Years Predicts Improved Transplant-Free Survival
NEWARK, Calif., May 23, 2022 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical…
RAPT Therapeutics Announces Initiation of Phase 2b Trial of RPT193 in Patients with Moderate-to-Severe Atopic Dermatitis
SOUTH SAN FRANCISCO, Calif., May 23, 2022 (GLOBE NEWSWIRE) — RAPT Therapeutics, Inc. (Nasdaq: RAPT),…
Positive Results from VISEN’s Phase 3 Trial of Once-Weekly TransCon hGH in China Consistent with Ascendis Pharma’s Phase 3 Height Trial
– VISEN’s Phase 3 Trial achieved primary endpoint; pediatric growth hormone deficiency (GHD) patients treated…
Ascendis Pharma A/S Announces New Commercial Endocrinology Leadership Appointments
– Joe Kelly has been appointed to the newly created role of Head of U.S….
Recce Pharmaceuticals Announces Positive Safety Data from Fifth Cohort of Phase I Clinical Trial of RECCE® 327 and Initiates Sixth Cohort at 4,000mg
Highlights: In cohort five, RECCE® 327 (R327) demonstrated good safety and tolerability in subjects intravenously…
Enlivex Appoints Dr. Roger J. Pomerantz to its Board of Directors as Vice Chairman
Former Worldwide Head of Licensing and Acquisition and Knowledge Management at Merck & Co., where…
Ocugen, Inc. to Present at H.C. Wainwright Global Investment Conference
MALVERN, Pa., May 23, 2022 (GLOBE NEWSWIRE) — Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company…